Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes Published March 29, 2025 N Engl J Med 2025;392:2001-2012 DOI: 10.1056/NEJMoa2501006 Abstract Background The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk
Comprehensive evaluation should include complete thyroid panel (not just TSH), fasting insulin and HOMA-IR for insulin resistance assessment, cortisol testing for adrenal dysfunction, sex hormone panel (testosterone, estrogen, progesterone), sleep study if sleep apnea is suspected, medication review for weight-promoting drugs, and psychological evaluation for eating disorders or food addiction
Studies show that GLP-1s decrease pain/stiffness, protect cartilage, and improve mobility, possibly preventing surgery for some
But their efficacy doesn't stop there